Animalcare Group PLC is active in the healthcare division in the United Kingdom. It is a generic veterinary medicines company. The company mainly caters to veterinary professionals in the treatment of companion animals through a product line comprised of licensed veterinary medicines and companion animal identification products and services. Its only reportable segment is Pharmaceutical which includes the development and marketing of innovative pharmaceutical products. The company has a presence in Belgium, The Netherlands, Germany, Italy, Portugal, the European Union - Other, Asia, Middle East Africa, Spain, the United Kingdom, and Other Countries of which Spain derives the majority of the revenue to the company.
1972
201
LTM Revenue $109M
LTM EBITDA $19.3M
$280M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Animalcare Group has a last 12-month revenue (LTM) of $109M and a last 12-month EBITDA of $19.3M.
In the most recent fiscal year, Animalcare Group achieved revenue of $99.7M and an EBITDA of $17.9M.
Animalcare Group expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Animalcare Group valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $109M | XXX | $99.7M | XXX | XXX | XXX |
Gross Profit | $61.5M | XXX | $55.4M | XXX | XXX | XXX |
Gross Margin | 56% | XXX | 56% | XXX | XXX | XXX |
EBITDA | $19.3M | XXX | $17.9M | XXX | XXX | XXX |
EBITDA Margin | 18% | XXX | 18% | XXX | XXX | XXX |
EBIT | $14.9M | XXX | $9.5M | XXX | XXX | XXX |
EBIT Margin | 14% | XXX | 10% | XXX | XXX | XXX |
Net Profit | $8.6M | XXX | $24.8M | XXX | XXX | XXX |
Net Margin | 8% | XXX | 25% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $12.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Animalcare Group's stock price is GBP 3 (or $4).
Animalcare Group has current market cap of GBP 197M (or $265M), and EV of GBP 209M (or $280M).
See Animalcare Group trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$280M | $265M | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Animalcare Group has market cap of $265M and EV of $280M.
Animalcare Group's trades at 2.8x EV/Revenue multiple, and 15.6x EV/EBITDA.
Equity research analysts estimate Animalcare Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Animalcare Group has a P/E ratio of 30.8x.
See valuation multiples for Animalcare Group and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $265M | XXX | $265M | XXX | XXX | XXX |
EV (current) | $280M | XXX | $280M | XXX | XXX | XXX |
EV/Revenue | 2.6x | XXX | 2.8x | XXX | XXX | XXX |
EV/EBITDA | 14.5x | XXX | 15.6x | XXX | XXX | XXX |
EV/EBIT | 18.8x | XXX | 29.5x | XXX | XXX | XXX |
EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
P/E | 30.8x | XXX | 10.7x | XXX | XXX | XXX |
EV/FCF | 26.5x | XXX | 25.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnimalcare Group's last 12 month revenue growth is 15%
Animalcare Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Animalcare Group's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Animalcare Group's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Animalcare Group and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 15% | XXX | 14% | XXX | XXX | XXX |
EBITDA Margin | 18% | XXX | 18% | XXX | XXX | XXX |
EBITDA Growth | 32% | XXX | 24% | XXX | XXX | XXX |
Rule of 40 | 31% | XXX | 33% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Animalcare Group acquired XXX companies to date.
Last acquisition by Animalcare Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Animalcare Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was Animalcare Group founded? | Animalcare Group was founded in 1972. |
Where is Animalcare Group headquartered? | Animalcare Group is headquartered in United Kingdom of Great Britain and Northern Ireland. |
How many employees does Animalcare Group have? | As of today, Animalcare Group has 201 employees. |
Who is the CEO of Animalcare Group? | Animalcare Group's CEO is Ms. Jennifer Ann Julia Winter. |
Is Animalcare Group publicy listed? | Yes, Animalcare Group is a public company listed on LON. |
What is the stock symbol of Animalcare Group? | Animalcare Group trades under ANCR ticker. |
When did Animalcare Group go public? | Animalcare Group went public in 2008. |
Who are competitors of Animalcare Group? | Similar companies to Animalcare Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Animalcare Group? | Animalcare Group's current market cap is $265M |
What is the current revenue of Animalcare Group? | Animalcare Group's last 12 months revenue is $109M. |
What is the current revenue growth of Animalcare Group? | Animalcare Group revenue growth (NTM/LTM) is 15%. |
What is the current EV/Revenue multiple of Animalcare Group? | Current revenue multiple of Animalcare Group is 2.6x. |
Is Animalcare Group profitable? | Yes, Animalcare Group is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Animalcare Group? | Animalcare Group's last 12 months EBITDA is $19.3M. |
What is Animalcare Group's EBITDA margin? | Animalcare Group's last 12 months EBITDA margin is 18%. |
What is the current EV/EBITDA multiple of Animalcare Group? | Current EBITDA multiple of Animalcare Group is 14.5x. |
What is the current FCF of Animalcare Group? | Animalcare Group's last 12 months FCF is $10.6M. |
What is Animalcare Group's FCF margin? | Animalcare Group's last 12 months FCF margin is 10%. |
What is the current EV/FCF multiple of Animalcare Group? | Current FCF multiple of Animalcare Group is 26.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.